source
- J&J and Contineum's oral M1 inhibitor fails second mid-stage depression trialContineum Therapeutics and Johnson & Johnson reported that their oral M1 receptor inhibitor, known as PIPE-307 or JNJ-5120, did not meet its primary endpoints in a Phase II study for major depressi…
- FDA approves first radioligand generic, pitting Curium against Novartis' LutatheraThe U.S. Food and Drug Administration has granted approval to Curium’s radioligand product, the first generic in this therapeutic class. The approved drug is a direct equivalent of Novartis’ Lutat…